Monte Rosa Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Monte Rosa Therapeutics's estimated annual revenue is currently $9.5M per year.
- Monte Rosa Therapeutics's estimated revenue per employee is $63,456
- Monte Rosa Therapeutics's total funding is $223.5M.
Employee Data
- Monte Rosa Therapeutics has 149 Employees.
- Monte Rosa Therapeutics grew their employee count by 24% last year.
Monte Rosa Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP, Discovery Sciences | Reveal Email/Phone |
3 | SVP, Chemical Sciences and Process Development | Reveal Email/Phone |
4 | Head CADD and Computational Chemistry | Reveal Email/Phone |
5 | VP, Head Chemistry | Reveal Email/Phone |
6 | VP Intellectual Property | Reveal Email/Phone |
7 | SVP and General Counsel | Reveal Email/Phone |
8 | VP Nonclinical Development & Clinical Pharmacology | Reveal Email/Phone |
9 | SVP, Head Business Development | Reveal Email/Phone |
10 | SVP Chemistry | Reveal Email/Phone |
Monte Rosa Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Monte Rosa Therapeutics?
Small molecule protein degraders are set to reshape the way by which diseases will be treated. Our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. Headquartered in Boston with additional laboratory facilities in Basel, Monte Rosa Therapeutics is a private company launched in 2020. Initially seeded by Versant Ventures and incubated at Ridgeline Discovery in Basel, and The Institute of Cancer Research in London, Monte Rosa has raised $32.5 million from Versant and New Enterprise Associates. Academic co-founders are Prof. Raj Chopra and Prof. Ian Collins of The Institute for Cancer Research, UK.
keywords:N/A
$223.5M
Total Funding
149
Number of Employees
$9.5M
Revenue (est)
24%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Monte Rosa Therapeutics News
Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven...
BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular...
After VectivBio, Gain Therapeutics, Pharvaris and NLS Pharmaceutics, Monte Rosa Therapeutics is already the fifth biotech company with Swiss roots going public on Nasdaq in 2021. Monte Rosa Therapeutics is developing a portfolio of novel small molecule precision medicines that employ the body’s ...
Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine based in Basel and is active in both Boston and Basel. With the core focus on discovering and developing molecular glues to degrade disease-causing proteins, the company has created a platform to rational ...
Monte Rosa Therapeutics, a Boston, MA-based biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, closed a $95m Series C financing. The round was led by Avoro Capital Advisors with participation from additional new investors Fidel ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $41M | 149 | -12% | N/A |
#2 | $38.4M | 149 | 9% | N/A |
#3 | $24.6M | 149 | 3% | N/A |
#4 | $15M | 149 | -68% | N/A |
#5 | N/A | 149 | -10% | N/A |